Biotricity Inc. (Biotricity) today announced its financial results and provided a business update for its third quarter of fiscal 2023 ended December 31, 2022. Commenting, Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “With our suite of state-of-the-art remote cardiac solutions now well established, Biotricity is focused on sales, marketing and achieving positive cash flow.”
Biotricity Inc. (Biotricity) has signed its second distribution agreement with a top five US medical device distributor for the marketing and distribution of its two cardiac monitoring solutions (CMS) designed for cardiologists’ patient use – Bioflux® and BiotresTM. The distribution agreement covers Bioflux and Biotres and will be distributed directly to hospitals and clinics for professional medical utilization with suitable patients.
Biotricity Inc. (Biotricity) has signed an agreement with a leading group purchasing organization (“GPO”) for national distribution of its cardiac monitoring solutions, Bioflux® and BiotresTM. Both Bioflux and Biotres are designed for cardiologists to diagnose and monitor their patients remotely. GPO’s are entities comprised of businesses organized to purchase materials or supplies from vendors in larger volumes to gain efficiency. In this case, the GPO is comprised of hundreds of small, independent US hospitals, private clinics, and medical offices that purchase medical devices and supplies at scale.
Biotricity Inc. (Biotricity) today announced that it made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a new form factor of its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients.
Biotricity Inc. (Biotricity) today announced it has surpassed $10 million in annual revenue run rate. “With strong revenue growth each quarter, our scale and market reach increases every day. I am committed to continuing to drive growth and realize our potential,” says Biotricity Founder and CEO, Dr. Waqaas Al-Siddiq.
Biotricity Inc. (Biotricity) has signed a distribution agreement with one of the Top 10 US medical device distributors to distribute its cardiac monitoring solutions, Bioflux and Biotres. With the commercialization of its Bioflux and Biotres products, Biotricity has increased its total addressable market from $1 billion to approximately $6 billion.
Biotricity Inc. (Biotricity) today announced its financial results and provided a business update for its fiscal 2023 second quarter ended September 30, 2022.
Biotricity Inc. (Biotricity) today announced that its Bioheart device has been named to TIME’s list of the Best Inventions of 2022. Bioheart is the first of its kind – a continuous heart rhythm monitor using advanced technology to deliver unlimited heart data insights.
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced the U.S. launch of Biocare Cardiac. The national roll-out follows two successful pilot programs in Oklahoma City with CardioVascular Health Clinic, a medical facility providing high-quality cardiovascular care to more than 40,000 patients, and a four-month pilot with Lexington Heart Specialists in Kentucky, a medical practice providing high-quality cardiovascular care to more than 20,000 patients.
Biotricity Inc. (Biotricity) today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux®, Biotricity’s high-precision, single-unit mobile cardiac telemetry device that provides real-time monitoring and transmission of the patient’s ECG information, has captured billions of heartbeats to date, monitored in real-time by Bioflux’s built in algorithms, certified cardiac technicians and benchmarked by Artificial Intelligence (AI).
